Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease, or hepatic disease. They are also indicated for the treatment of hypertension, to lower blood pressure, reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Control of high blood pressure should be part of comprehensive cardiovascular risk management.
Mechanism of Action
Torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, inhibiting the Na+/K+/2Cl– carrier system, confirmed in clinical pharmacology studies. Diuretic activity correlates with drug excretion rate. It increases urinary excretion of sodium, chloride, and water, without altering glomerular filtration rate or renal plasma flow. With oral dosing, diuresis onset is within 1 hour, peaking during the first or second hour, lasting 6 to 8 hours. Sodium excretion increases linearly with dose up to 20 mg. In controlled trials, patients with heart failure achieved greater reductions in weight and edema with 10 mg to 20 mg daily doses compared to placebo. In hypertensive patients, the recommended initial dose is 5 mg once daily, titrating to 10 mg if needed, after 4 to 6 weeks. The antihypertensive effect is near maximal after 4 to 6 weeks, with systolic and diastolic blood pressure reductions.
Drug Interactions and Considerations
Torsemide has been administered with β-adrenergic blocking agents, ACE inhibitors, and calcium-channel blockers without observed adverse drug interactions. The bioavailability of torsemide tablets is approximately 80%, with small inter-subject variation. The drug is absorbed with little first-pass metabolism. Daily sodium loss comes into balance with dietary sodium intake with chronic administration. Sudden discontinuation of torsemide results in blood pressure returning to pretreatment levels over several days.”